Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-002 Suppository in Ulcerative Proctitis
NCT01016262Phase 3Terminated
- Sponsor
- Forest Laboratories
- Start
- Nov 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in ulcerative proctitis (6 arms), sponsored by Forest Laboratories. Primary endpoint: Percentage of Participants Who Were Responders at Week 6. Started Nov 2009; status: terminated.
02
Drugs
Salcrozine
03
Conditions
ulcerative proctitis
Beyond the preview
Go deeper on NCT01016262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01016262.